advanced and progressive pancreatic panNETs. Switching between both upon progression
is a common strategy, but the best sequence is not yet well established. Methods SEQTOR
trial aims to compare the progression-free survival rate to 1st treatment (PFS1) at 12 months
(m) in STZ-based CT vs Everolimus. Secondary endpoints included objective response rate
(ORR), clinical benefit rate (CBR), median PFS1 (mPFS1) and PFS to 2nd treatment (PFS2) …